MissionIR Articles

Regenerative medicine has long promised to transform patient care, but investors often become most interested when innovative science begins transitioning toward commercial adoption. Regentis Biomaterials (NYSE American: RGNT) is approaching that transition with GelrinC(R), its cartilage regeneration platform…

Regentis Biomaterials (NYSE American: RGNT) is taking aim at a $3 billion U.S. market with what could be the first true off-the-shelf solution for knee cartilage repair—no cells, no delays, no complexity. Its GelrinC(R) platform delivers…

Knee cartilage damage remains one of the most stubborn problems in orthopedic medicine. Unlike many other tissues in the body, articular cartilage has little natural ability to heal because it lacks both direct blood supply…

Regentis Biomaterials (NYSE American: RGNT) announced a collaboration with Humanitas Research Hospital in Milan, Italy, to support expanding clinical activities and commercial strategy for GelrinC(R) in Europe, where the product has CE Mark approval for…

Regentis Biomaterials (NYSE American: RGNT) announced the development of a new proprietary solvent-free manufacturing process for GelrinC(R), its off-the-shelf hydrogel implant for treating focal articular knee cartilage injuries, that more than quadruples production yield per…

Regentis Biomaterials (NYSE American: RGNT) reported financial results for the year ended Dec. 31, 2025, and provided a corporate and clinical update highlighting progress in its pivotal Phase III study of GelrinC(R) for knee cartilage…

Regentis Biomaterials (NYSE American: RGNT), a regenerative medicine company focused on tissue repair solutions, today announced the appointment of Dr. Galit Reske, PhD, as chief medical officer. Dr. Reske brings extensive experience in clinical development,…

Regentis Biomaterials (NYSE American: RGNT) announced the expansion of its European clinical site network into new markets, including Italy and Eastern Europe, to support ongoing clinical programs and the commercial strategy for GelrinC(R), which has…

Regentis Biomaterials (NYSE American: RGNT) announced the appointment of Ori Gon as chief financial officer and chief business officer, effective immediately. Gon will oversee the company’s commercial and business development initiatives, as well as financial…

Regentis Biomaterials (NYSE American: RGNT) announced the expansion of its U.S. clinical site network to support its ongoing pivotal Phase III study of GelrinC(R) for knee cartilage repair and future clinical programs. The expanded network…

Regentis Biomaterials (NYSE American: RGNT) announced new long-term imaging data from its completed European clinical trial of GelrinC(R), showing regenerated cartilage with internal structural organization closely resembling healthy native hyaline cartilage. Published in the peer-reviewed…

Regentis Biomaterials (NYSE American: RGNT) today announced publication of long-term follow-up results from its completed Phase II clinical trial of GelrinC(R) in the peer-reviewed journal Cartilage, highlighting durable cartilage regeneration at 24 months. The study…